Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: epirubicin - cyclophosphamide / docetaxel|DRUG: epirubicin - cyclophosphamide / docetaxel + bevacizumab|DRUG: paclitaxel|DRUG: paclitaxel + everolimus (RAD001)|DRUG: epirubicin - cyclophosphamide / docetaxel + trastuzumab|DRUG: epirubicin - cyclophosphamide / docetaxel + lapatinib
Sponsor: German Breast Group
Collaborators: AGO Study Group